Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy
- 1 January 2015
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 197, 180-189
Abstract
No abstract availableKeywords
Funding Information
- Bio & Medical Technology Development Program (2012028833)
- Basic Science Research Program (2010-0027955)
- MSIP (2010-0027955)
This publication has 32 references indexed in Scilit:
- Effect of Tumor Microenvironment on Tumor VEGF During Anti-VEGF Treatment: Systems Biology PredictionsJNCI: Journal of the National Cancer Institute, 2013
- Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imagingNature Medicine, 2012
- Improving Delivery and Efficacy of Nanomedicines in Solid Tumors: Role of Tumor PrimingNanomedicine, 2011
- Heterogeneity in breast cancerJournal of Clinical Investigation, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Analysis of the Complex Formation of Heparin with Protamine by Light Scattering and Analytical Ultracentrifugation: Implications for Blood Coagulation ManagementJournal of the American Chemical Society, 2010
- Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically OrganizedCancer Cell, 2010
- Heparin‐based nanoparticlesWIREs Nanomedicine and Nanobiotechnology, 2009
- Biomarkers of response and resistance to antiangiogenic therapyNature Reviews Clinical Oncology, 2009
- Molecular and cellular biomarkers for angiogenesis in clinical oncologyDrug Discovery Today, 2007